The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors

詳細情報 詳細情報について

• CRID

  1363107370569569152

• DOI

  10.1159/000336143

• ISSN

  14219794

  00093157

• Web Site

  https://www.karger.com/Article/Pdf/336143

  http://www.karger.com/Article/Pdf/336143

• データソース種別

  • Crossref